We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 11 oktober 2018

Press release: Roche CoaguChek device producing inaccurate results

Press release: Roche CoaguChek device producing inaccurate results
MHRA are asking people who use the CoaguChek device to check their test strips as a precaution following an alert by the manufacturer Roche.
Lees verder

Press release: UK and Indian authorities clamp down on international medicines crime
The Medicines and Healthcare products Regulatory Agency (MHRA) are working closely with law enforcement agencies in India to prevent unlicensed medicines entering the UK.
Lees verder

Medical Device Alerts issued in September 2018
Alerts were recently issued by MHRA about flex connectors in Halyard closed suction kits; SureSigns VS & VM patient monitors and viewing stations; and Zimmer Biomet trauma guide wires.
Lees verder

Letters and drug alerts sent to healthcare professionals in September 2018
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram adrenaline autoinjectors. MHRA issued alerts and recalls for batches of Olmetec, Mydriasert, Caspofungin, and Imatinib.
Lees verder

Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children
Provide clear information to patients and caregivers about how to minimise the risk of accidental exposure and the importance of appropriate disposal of patches. We continue to receive reports of unintentional opioid toxicity and overdose of fentanyl due to accidental exposure to patches.
Lees verder

Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
Interrupt treatment if posterior reversible encephalopathy syndrome (PRES) is confirmed and resume treatment only once the event is resolved and the benefit of continued treatment outweighs the risk of PRES.
Lees verder